Depression following pegylated interferon-alpha: characteristics and vulnerability

Area of Science:

• Psychiatry
• Hepatology
• Pharmacology

Background:

• Interferon-alpha (IFN-alpha) therapy is used for Hepatitis C.
• IFN-alpha treatment is associated with potential psychiatric side effects, including depression.
• Understanding patient vulnerability is crucial for managing treatment.

Purpose of the Study:

• To characterize depression induced by IFN-alpha2 treatment.
• To investigate the correlation between pre-treatment temperament and vulnerability to IFN-alpha-induced depression.
• To identify predictive factors for psychiatric adverse events during IFN-alpha therapy.

Main Methods:

• Prospective monitoring of 23 euthymic adults undergoing year-long PEG-IFN-alpha treatment for Hepatitis C.
• Utilized Structured Clinical Interview for DSM-IV (SCID) and self-report questionnaires at baseline and during treatment.
• Employed principal component analysis to analyze changes in self-report scores.

Main Results:

• Major depressive episodes developed in 39% of patients within 3 months.
• Treatment led to increased depression (Beck Depression Inventory, Hospital Anxiety and Depression Scale), hostility, anxiety, and general somatic symptoms.
• Baseline Beck Depression Inventory predicted 1-month BDI scores (r=0.76).
• Low baseline agreeableness predicted 1-month hostility (r=0.75).
• High baseline neuroticism and low agreeableness predicted major depression, controlling for baseline BDI (r=0.66).

Conclusions:

• IFN-alpha treatment has a depressogenic effect on a subset of vulnerable individuals.
• Some patients exhibit independent vulnerability to worsened hostility.
• Pre-treatment personality assessment may help predict clinical vulnerabilities to IFN-alpha therapy.